Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0677930 (primary tumor)
 20,210 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The Southwest Oncology Group in a prospective randomized study compared one year of adjuvant combination chemotherapy with continuous CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone) to two years of intermittent L-phenylalanine mustard (L-PAM) in women with operable breast cancer with histologically positive axillary lymph nodes. In fully and partially evaluable patients with a 68-month median follow-up, treatment failures have occurred in 27% of 172 receiving CMFVP and 47% of 186 women given L-PAM (p = 0.002). The advantage for women receiving CMFVP was seen for all subsets regardless of menopausal status except among women who were premenopausal and had 1-3 positive nodes. Based on this study, a second study was implemented using both the estrogen-receptor (ER) content of the primary tumor and axillary nodal status to select therapy.
 ...
PMID:Adjuvant therapy of breast cancer: the Southwest Oncology Group experience. 636 57

Between July 1975 and June 1979, 194 patients with State II or III breast carcinoma were randomized to receive either L-phenylalanine mustard (L-PAM), cyclophosphamide and 5-fluorouracil and prednisolone (CFP), or CFP and BCG. Sixty-one patients have recurred despite the adjuvant chemoimmunotherapy trial. Fifty-three are evaluable for survival and 36 for response to chemo-hormonal therapy. Those treated with a chemo-hormonal regimen for their first recurrence exhibited a 53% objective response rate to cytotoxic therapy or a 35% response to hormonal therapy. Prior exposure to L-PAM, cyclophosphamide, or 5-fluorouracil did not preclude response to "salvage" therapy regimens containing those agents. Neither menopausal status, estrogen receptor content, size of the primary tumor, adjuvant treatment, nor extent of the recurrence had any effect on subsequent survival. Overall, the entire group exhibited median survival of 37 months from initial diagnosis and 13 months from recurrence. Unlike recurrent Hodgkin's disease, there was no demonstrable relationship between the length of the disease-free interval and the likelihood of subsequent response to cytotoxic or hormonal treatment. Comparison is made to the results of "salvage" therapy administered after three other large adjuvant treatment series.
 ...
PMID:Treatment of breast carcinoma recurrent after adjuvant chemoimmunotherapy. 638 84

Brown Norway (BN) rats were implanted twice with allogeneic (Lewis strain) Moloney sarcoma tumors (LM-2) and serum samples were assessed for Raji binding activity during primary and secondary tumor growth and rejection. Maximum Raji binding was observed 25 days after a primary tumor implant; thereafter, the binding activity decreased. Accelerated tumor rejection was observed after a second tumor implant and was associated with a 3-fold increase in serum Raji binding activity which remained elevated up to 40 days post-tumor implant. Raji binding activity in hyperimmune rats co-migrated with IgG in G-200 fractionated serum. Polyacrylamide gel electrophoresis (PAGE) revealed the presence of bovine serum albumin (BSA) on Raji cell membranes which reacted immunochemically with rabbit anti-BSA antiserum. Immunodiffusion studies revealed that sera from hyperimmune rats produced a precipitin band when reacted with Noniodet P-40 (NP-40) lysates of Raji cells and formed a line of identity with BSA.
 ...
PMID:Detection of Raji binding activity in hyperimmune allogeneic tumor bearing sera associated with anti-BSA activity. 698 Jan 87